MK-1293

insulin analogue? (MK-1293 is a follow-on insulin lispro-like agent) · Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for MK-1293, covering 2017-03-08 to 2017-03-08. Get the full timeline:

Most recent: Clinical Trial Update: The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006) [Phase 3]

See pricing